<DOC>
	<DOCNO>NCT00630968</DOCNO>
	<brief_summary>The purpose study obtain information optimal dose efficacy Keppra daily clinical practice , confirm favorable safety tolerability profile drug observe clinical development .</brief_summary>
	<brief_title>S.K.A.T.E . : Safety Keppra Adjunctive Therapy Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Partial onset seizure , whether secondarily generalize ; least 1 partial seizure 14 partial seizure per month measure historic baseline ; use 1 , 2 concomitant market antiepileptic drug ( AEDs ) time study entry . Presence known pseudoseizures within last year ; presence history allergy component Keppra ( levetiracetam , lactose , cornstarch , excipients ) pyrrolidine derivative ; felbamate less 18 month exposure ; vigabatrin , visual field assess per recommendation manufacturer , i.e. , every 6 month ; uncountable seizure ( cluster ) history convulsive status epilepticus within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>